Galecto Inc. Stock Price, News & Analysis

Galecto, Inc. (NASDAQ: GLTO), a biotechnology firm, announced participation in H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022. Management will engage in virtual 1x1 meetings with investors, and a webcast of the presentation will be available for replay on Galecto’s website. The company focuses on developing inhibitors for fibrosis and cancer, with four ongoing Phase 2 clinical trials targeting conditions like idiopathic pulmonary fibrosis and non-small cell lung cancer.

Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology firm, has published a study in the Journal of Cancer Research and Clinical Oncology that highlights the role of galectin-3 in cancer treatment. The research shows that high levels of galectin-3 are linked to reduced survival rates in cancer patients, suggesting that Galecto's oral candidate GB1211 could enhance the effectiveness of checkpoint inhibitors like atezolizumab. Ongoing Phase 2a trials evaluate GB1211’s performance in non-small cell lung cancer (NSCLC).

Galecto, Inc. (NASDAQ: GLTO) reported its Q2 2022 financial results, highlighting significant advancements in its clinical pipeline. The company completed enrollment in the Phase 2b GALACTIC-1 trial for idiopathic pulmonary fibrosis (IPF) and initiated the Phase 2a GALLANT-1 trial for non-small cell lung cancer (NSCLC). Cash and investments stood at approximately $85.9 million, expected to sustain operations into H2 2024. However, the net loss attributable to common stockholders increased to $16.9 million, or $(0.67) per share, compared to $12.3 million, or $(0.49) per share, in the prior year.

Galecto, Inc. (GLTO) has initiated the Phase 2a GALLANT-1 trial, enrolling the first patient to study GB1211, a galectin-3 inhibitor, in combination with Roche's atezolizumab for treating non-small cell lung cancer (NSCLC). This trial seeks to assess the efficacy of GB1211 in enhancing checkpoint inhibition. Pre-clinical studies indicate GB1211's potential to diminish tumor growth and metastasis. Topline data is expected in mid-2023, as Galecto continues its focus on targeted cancer therapies.

Galecto, Inc. (NASDAQ: GLTO) announced its participation at the Jefferies Healthcare Conference, scheduled for June 8-10, 2022, in New York City. The presentation will occur at 3:00 PM ET, and a live webcast will be available on Galecto's investor website. The company is dedicated to developing treatments for cancer and fibrosis, with ongoing clinical trials including GB0139 for idiopathic pulmonary fibrosis and GB2064 for myelofibrosis. For further details, visit their website.

Galecto, Inc. (NASDAQ: GLTO) announced two significant poster presentations for its oral galectin-3 inhibitor, GB1211, at the 2022 ASCO Annual Meeting. The first poster presents findings that GB1211 reverses galectin-3 induced blockade of PD-1/PD-L1 checkpoint inhibitors, potentially enhancing their effectiveness in cancer treatment. The second poster outlines the GALLANT-1 trial, a Phase 2 study examining the combination of GB1211 and atezolizumab in non-small cell lung cancer (NSCLC) patients. The presentations will occur between June 5-6, 2022, and will be accessible on Galecto's website.

On May 2, 2022, Galecto, a clinical stage biotechnology company (NASDAQ: GLTO), announced its participation in two upcoming healthcare conferences. Management will present at the BofA Securities 2022 Healthcare Conference on May 10 at 3:40 pm ET. An additional H.C. Wainwright Global Investment Conference will take place from May 23-26, featuring an on-demand presentation. Galecto is focused on developing treatments for cancer and fibrosis, with several ongoing clinical trials, including for idiopathic pulmonary fibrosis and myelofibrosis.

Galecto, Inc. (NASDAQ: GLTO) reported its financial results for Q1 2022, highlighting significant progress in clinical trials. The company completed enrollment in two Phase 2 trials—GALACTIC-1 for idiopathic pulmonary fibrosis (IPF) and GULLIVER-2 for liver cirrhosis. The total net loss increased to $16.9 million, or $(0.67) per share, from $13.3 million, or $(0.53) per share, year-over-year. As of March 31, 2022, Galecto had approximately $101.8 million in cash and equivalents, expected to fund operations into late 2024.

Galecto, Inc. (NASDAQ: GLTO) announced the completion of patient enrollment for its Phase 2b GALACTIC-1 trial of GB0139, an inhaled galectin-3 inhibitor for idiopathic pulmonary fibrosis (IPF). The trial, involving 141 patients at 100 centers globally, aims to assess the drug's safety and efficacy over 52 weeks. IPF affects around 100,000 people in the U.S., presenting a critical unmet medical need. Results are expected in mid-2023, with GB0139 targeting a significant gap in IPF treatment options.